ARTICLE | Clinical News
Therion begins two Phase II trials
September 7, 2000 7:00 AM UTC
Under a CRADA, Therion ( Cambridge, Mass.) and the National Cancer Institute began two additional Phase II trials of Prostvac VF, a live recombinant vaccine consisting of a vaccinia virus vector encod...